Results from Professor John Petrie's REMOVAL trial announced in San Diego

An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes, according to a new global trial led by Professor John Petrie Image of Prof John Petriefrom the Institute of Cardiovascular and Medical Sciences. The REMOVAL trial’s results, announced in June at the American Diabetes Association’s conference in San Diego, and published in the journal The Lancet Diabetes and Endocrinology, show how the drug metformin has potentially beneficial effects on cardiovascular and metabolic outcomes in adults with longstanding type 1 diabetes. The REMOVAL trial, co-sponsored by the University of Glasgow and NHS GGC in the UK and mainland Europe, is the largest clinical trial of metformin therapy in type 1 diabetes to date and has provided clinically meaningful data on metformin’s potential to reduce the risk of developing cardiovascular disease. Read more.

First published: 31 July 2017